Company: APM
Filing Date: 2025-07-15
Form Type: DRS
Source: 0001213900-25-063899
Chunk: 164

Company: Aptorum Group Ltd
Filing Date: 2025-07-15
Form: DRS
Chunk 164
---
 parties, the value of its brand and other intangible
assets may be diminished and its competitors may be able to more effectively mimic its technologies, offerings, or features or methods
of operations. Even if DiamiR does detect violations or misappropriations and decide to enforce its rights, litigation that may be necessary
to enforce its rights may not be pursued by DiamiR, as it may be time-consuming and expensive, and divert its management’s attention.
Additionally, a court of a competent jurisdiction may determine that certain of DiamiR’s intellectual property rights are unenforceable.
If DiamiR fails to protect its intellectual property and data in a cost-effective and meaningful manner, its competitive standing could
be harmed and the brand, reputation, business, results of operations, and financial condition could be materially adversely affected.

Intellectual Property infringement claims by other companies could result in costly disputes and could limit Diamir’s ability to sell its products.

Litigation over intellectual
property is prevalent in the molecular diagnostics industry. As the market for molecular diagnostics continues to grow and the number
of participants in the market increases, DiamiR may increasingly be subject to patent infringement claims. While DiamiR may attempt to
obtain licenses to such patents, DiamiR may be unable to do so on favorable terms, or at all. Additionally, if its products are found
to infringe third-party patents, DiamiR may be required to pay damages and/or lose the ability to sell certain products, causing its revenues
to decrease or causing damage to DiamiR’s reputation in the industry also leading to a material adverse effect on DiamiR’s
business.

If product liability lawsuits are successfully brought against DiamiR, DiamiR may incur substantial liabilities and may have to limit or cease sales of its products.

The testing, manufacturing,
and marketing of medical diagnostic products involves an inherent risk of product liability claims. If DiamiR cannot successfully defend
itself against product liability claims, DiamiR may incur substantial liabilities or be required to limit or cease sales of its products.
In addition, a defect in the design or manufacture of DiamiR’s products could have a material adverse effect on DiamiR’s reputation
in the industry and subject DiamiR to claims of liability for injury and otherwise. Any substantial loss resulting from such a claim could
have a material adverse effect on DiamiR’s profitability and the damage to DiamiR’s reputation in the industry could have
a material adverse effect on Diami